Brachytherapy Market Report 2026

Brachytherapy Market Overview

• Brachytherapy market size has reached to $1 billion in 2025 • Expected to grow to $1.42 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Impact Of Increasing Cancer Burden On The Brachytherapy Market • Market Trend: Advancements In Brachytherapy Solutions For Cancer Care Facilities • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Brachytherapy Market?

Brachytherapy is a form of radiotherapy where radioactive sources are placed directly into or near the tumor. This allows for the targeted delivery of radiation to cancerous tissues while minimizing exposure to surrounding healthy tissues. It's commonly used to treat prostate, cervical, and skin cancers, among others, offering a localized and effective treatment option. The main types of brachytherapy are applicators and afterloaders, and electronic brachytherapy. Applicators are devices used to deliver radioactive sources directly to treatment sites, while afterloaders automate the process of placing these sources, ensuring precision and safety in brachytherapy treatments. The dose type of brachytherapy includes high-dose rate (HDR) brachytherapy, and low-dose rate (LDR) brachytherapy applied in treatments for prostate cancer, gynecological cancer, breast cancer, and other medical conditions. The end users typically include hospitals, specialty clinics, and others.

What Is The Brachytherapy Market Growth Forecast?

The brachytherapy market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to rising demand for image-guided and computer-assisted brachytherapy, growing uptake of electronic brachytherapy solutions, higher adoption in outpatient and specialty oncology clinics, increasing integration of precision planning and dosimetry tools, expanding application of brachytherapy across additional cancer indications. Major trends in the forecast period include increasing adoption of image-guided and precision-targeted brachytherapy procedures, rising use of brachytherapy in prostate, gynecological, and breast cancer treatment, growing preference for localized radiation delivery with reduced tissue exposure, expansion of electronic brachytherapy for outpatient and dermatologic applications, focus on improving treatment accuracy, patient outcomes, and therapy safety.

Global Brachytherapy Market Segmentation

1) By Product Type: Seeds, Applicators And Afterloaders, Electronic Brachytherapy 2) By Dosage Type: High-Dose Rate (HDR) Brachytherapy, Low-Dose Rate (LDR) Brachytherapy 3) By Application: Prostate Cancer, Gynecological Cancer, Breast Cancer, Other Applications 4) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Seeds: Iodine-125 Seeds, Palladium-103 Seeds, Cesium-131 Seeds, Other Radioactive Seeds 2) By Applicators And Afterloaders: Prostate Applicators, Vaginal Applicators, Interstitial Applicators, Skin Applicators, Afterloaders 3) By Electronic Brachytherapy: Electronic Brachytherapy Units, Electronic Brachytherapy Sources

What Is The Driver Of The Brachytherapy Market?

The increasing cancer burden is expected to propel the growth of the brachytherapy market going forward. The cancer burden is rising due to aging populations, lifestyle changes, and increased exposure to risk factors such as tobacco, poor diet, and environmental pollutants. Brachytherapy is used to manage the cancer burden by offering a targeted and effective treatment option that can be tailored to various types of cancer, providing localized therapy while minimizing overall treatment time and side effects. For instance, in September 2025, according to the Institute for Health Metrics and Evaluation (IHME), a US-based population health research organization, there were approximately 18.5 million new cancer cases in 2023, up from 18.0 million in 2022, highlighting a year‑on‑year rise in global cancer incidence. Therefore, the increasing cancer burden will drive the brachytherapy industry.

Key Players In The Global Brachytherapy Market

Major companies operating in the brachytherapy market are Elekta AB, IsoRay Inc, CIVCO Medical Solutions, Theragenics Corporation, Eckert & Ziegler BEBIG, IsoAid LLC, Best Medical International Inc, Boston Scientific Corporation, IBA Group, Accuray Incorporated, Cook Medical, Panacea Medical Technologies Pvt Ltd, NorthStar Medical Radioisotopes LLC, International Isotopes Inc, CivaTech Oncology Inc, Huiheng Medical Inc, Radiomedix, Mevion Medical Systems Inc, Qfix, Seno Medical Instruments

Global Brachytherapy Market Trends and Insights

Major companies operating in the brachytherapy market are focused on developing innovative technological solutions, such as standard afterloader technology, to enhance treatment precision and efficacy. Standard afterloader technology in brachytherapy refers to automated devices that deliver radioactive sources to tumor sites, ensuring precise radiation dose administration. For instance, in April 2024, Varian Medical Systems, a US-based medical device manufacturing company, partnered with Maastro, a US-based radiotherapy clinic, to launch an innovative brachytherapy applicator designed for accurate delivery of HDR brachytherapy in the treatment of rectal cancer. The new partially 3D-printed applicator was co-developed by Maastro radiation oncologists and physicists together with Varian experts to provide radiotherapists with improved treatment options for rectal cancer patients. The applicator is designed to increase contact with the tumor and provide a uniform dose distribution, with a dose range similar to that of contact X-ray brachytherapy (CXB).

What Are Latest Mergers And Acquisitions In The Brachytherapy Market?

In April 2024, GT Medical Technologies Inc., a US-based medical device manufacturing company, acquired Cesium-131 and related assets from Isoray Medical for an undisclosed amount. GT MedTech has strategically acquired Cesium-131 brachytherapy seed manufacturing capabilities to bolster its supply chain and strengthen its market position, emphasizing its dedication to increasing GammaTile adoption in the US. Isoray Medical is a US-based medical device manufacturing company that manufactures brachytherapy products for the treatment of cancer.

Regional Outlook

North America was the largest region in the brachytherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Brachytherapy Market?

The brachytherapy market consists of revenues earned by entities by providing services such as treatment planning, procedure administration, and post-treatment care. The market value includes the value of related goods sold by the service provider or included within the service offering. The brachytherapy market also includes sales of radioactive seeds, applicators, imaging and planning systems, and treatment delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.